Drug safety assessment of oral formulations of ketoconazole

Expert Opinion on Drug Safety

Volumn 14, Issue 2, 2015, Pages 325-334

  Gupta, Aditya K ^a,b   Daigle, Deanne ^b   Foley, Kelly A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

Author keywords

Antifungal; Ergosterol synthesis inhibitor; Hepatic injury; Hepatotoxicity; Imidazole; Ketoconazole; Liver injury; Mycosis

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; TERBINAFINE; TRIAZOLE; ANTIFUNGAL AGENT; ENDOCRINE DISRUPTOR;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; BLOATING; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HUMAN; JAUNDICE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALAISE; MYALGIA; NAUSEA; PANCYTOPENIA; PATIENT SAFETY; PRESCRIPTION; PRURITUS; REVIEW; RHABDOMYOLYSIS; SUICIDAL IDEATION; SWELLING; SYSTEMIC MYCOSIS; URTICARIA; DRUG INTERACTION; ORAL DRUG ADMINISTRATION; TOXIC HEPATITIS;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; ENDOCRINE DISRUPTORS; HUMANS; KETOCONAZOLE;

EID: 84921364691     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.983071     Document Type: Review

References (78)

1. Ketoconazole approved for systemic fungal infections. FDA Drug Bull. U.S. Food and Drug Administration 1981;11:18-19
2. Cucé LC, Wroclawski EL, Sampaio SA. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole. Int J Dermatol 1980;19:405-8
3. Varkey B. Oral antifungal therapy. Current status of ketoconazole. Postgrad Med 1983;73:52-3
4. Sohn CA. Evaluation of ketoconazole. Clin Pharm 1982;1:217-24
5. Thienpont D, Van Cutsem J, Van Gerven F, et al. Ketoconazole - a new broad spectrum orally active antimycotic. Experientia 1979;35:606-7
6. Heeres J, Backx LJ, Mostmans JH, Van Cutsem J. Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. J Med Chem 1979;22:1003-5
7. Heel RC, Brogden RN, Carmine A, et al. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982;23:1-36
8. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 1987;294:419-22
9. Stricker BH, Blok AP, Bronkhorst FB, et al. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 1986;3:399-406
10. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother 1981;19:1073-4
11. Craven PC. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1985;312:1061
12. D'Mello AP, D'Souza MJ, Bates TR. Pharmacokinetics of ketoconazoleantipyrine interaction. Lancet 1985;2:209-10
13. Magnasco AJ, Magnasco LD. Interaction of ketoconazole and ethanol. Clin Pharm 1986;5:522-3
14. Murphy E, Hannon D, Callaghan B. Ketoconazole-theophylline interaction. Ir Med J 1987;80:123-4
15. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole [Internet]. 2013. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2013/07/WC500146613.pdf [Cited 17 September 2014]
16. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Oral ketonconazole: do not prescribe or use for fungal infections - risk of liver injury outweighs benefits [Internet]. 2013. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON300403 [Cited 23 September 2014]
17. European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. European Medicines Agency 2013;1-3
18. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013
19. Health Canada. Health Canada Endorsed Important Safety Information on Ketoconazole [Internet]. Ketoconazole - Risk of Potentially Fatal Liver Toxicity - For Health Professionals. 2013. Available from: http://healthycanadians.gc.ca/recall-alert-rappelavis/hc-sc/2013/34173a-eng.php [Cited 17 September 2014]
20. Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(Suppl 1):S161-9
21. Borgers M, Van den Bossche H, De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am J Med 1983;74:2-8
22. Van den Bossche H, Willemsens G, Cools W, et al. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob Agents Chemother 1980;17:922-8
23. Rodriguez RJ, Acosta D. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995;96:83-92
24. Rodriguez RJ, Acosta D. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997;117:123-31
25. Administration AGD of HTG. Oral ketoconazole (Nizoral) 200 mg tablets [Internet]. Available from: http://www.tga.gov.au/safety/alerts-medicine-oral-etoconazole-131010.htm#.U0gmjfldWCk [Cited 11 April 2014]
26. Negroni R, Robles AM, Arechavala A, et al. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis. Rev Infect Dis 1980;2:643-9
27. Botter AA, Dethier F, Mertens RL, et al. Skin and nail mycoses: treatment with ketoconazole, a new oral antimycotic agent. Mykosen 1979;22:274-8
28. Graybill JR, Herndon JH, Kniker WT, Levine HB. Ketoconazole treatment of chronic mucocutaneous candidiasis. Arch Dermatol 1980;116:1137-41
29. Restrepo A, Stevens DA, Gómez I, et al. Ketoconazole: a new drug for the treatment of paracoccidioidomycosis. Rev Infect Dis 1980;2:633-42
30. Graybill JR, Lundberg D, Donovan W, et al. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis 1980;2:661-73
31. Legendre R, Steltz M. A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. Rev Infect Dis 1980;2:586-91
32. Borelli D. Treatment of pityriasis versicolor with ketoconazole. Rev Infect Dis 1980;2:592-5
33. Welsh O, González JG, Diaz M, et al. Therapeutic evaluation of ketoconazole in patients with coccidioidomycosis. Rev Infect Dis 1980;2:651-5
34. Jones HE, Simpson JG, Artis WM. Oral ketoconazole. An effective and safe treatment for dermatophytosis. Arch Dermatol 1981;117:129-34
35. Stevens DA, Stiller RL, Williams PL, Sugar AM. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. Am J Med 1983;74:58-63
36. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142:2137-40
37. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-8
38. Santen RJ, Van den Bossche H, Symoens J, et al. Site of action of low dose ketoconazole on androgen biosynthesis in men. J Clin Endocrinol Metab 1983;57:732-6
39. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144:2150-3
40. Pont A, Goldman ES, Sugar AM, et al. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med 1985;145:1429-31
41. Petersen EA, Alling DW, Kirkpatrick CH. Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial. Ann Intern Med 1980;93:791-5
42. Heiberg JK, Svejgaard E. Toxic hepatis during ketoconazole treatment. Br Med J (Clin Res Ed) 1981;283:825-6
43. Macnair A, Gascoigne E, Heap J, et al. Hepatitis and ketoconazole therapy. BMJ 1981;283:1058
44. Firebrace D. Hepatitis and ketoconazole therapy. BMJ 1981;283:1058-9
45. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983;74:80-5
46. Yan JY, Nie XL, Tao QM, et al. Ketoconazole associated hepatotoxicity: a systematic review and meta-analysis. Biomed Environ Sci 2013;26:605-10
47. Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009;15:2817-33
48. Janssen Pharmaceuticals, Inc. Nizoral Tablets Product Information [Internet]. 2011. Available from: http://www.janssen.com.au/files/Products/Nizoral-PI.pdf [Cited 17 September 2014]
49. Janssen Pharmaceuticals, Inc. SPORANOX (itraconazole) Capsules Product Information [Internet]. 2013. Available from: https://www.janssen.com.au/files/Products/SPORANOX-CAPSULES-PI.pdf [Cited 17 September 2014]
50. Pfizer Canada, Inc. DIFLUCAN 150∗ Fluconazole Capsule 150 mg Product Monograph [Internet]. 2010. Available from: http://www.pfizer.ca/en/our-products/products/monograph/178 [Cited 17 September 2014]
51. Pfizer Canada, Inc. VFEND (voriconazole) Tablets 50 mg and 200 mg For Injection 200 mg/ Vial (10 mg/mL when reconstituted) Powder for Oral Suspension 3 g/ bottle (40 mg/mL when reconstituted) Product Monograph [Internet]. 2013. Available from: http://www.pfizer.ca/en/our-products/products/monograph/140 [Cited 17 September 2014]
52. Novartis Pharmaceuticals Corp. Lamisil Prescribing Information [Internet]. 2013. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/Lamisil-tablets.pdf
53. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997;25:103-7
54. García Rodríguez LA, Duque A, Castellsague J, et al. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999;48:847-52
55. Kao W-Y, Su C-W, Huang Y-S, et al. Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 2014;77:180-9
56. Von Moltke L, Greenblatt D, Duan S, et al. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in-vitro. Pharm Pharmacol Commun 1998;4:443-5
57. Girois SB, Chapuis F, Decullier E, Revol BGP. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2006;25:138-49
58. Astellas Pharma US, Inc. AmBisome (amphotericin B) liposome for injection [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/050740s021lbl.pdf [Cited 23 October 2014]
59. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 2009;7:981-98
60. Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011;71:11-41
61. Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 2010;54:2409-19
62. Zhang C, Cheng J, Jiang Y, Liu J. Application of caspofungin in China compared with amphotericin B and fluconazole. Ther Clin Risk Manag 2014;10:737-41
63. Marques SA. Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. An Bras Dermatol 2013;88:700-11
64. Welsh O, Vera-Cabrera L, Rendon A, et al. Coccidioidomycosis. Clin Dermatol 2012;30:573-91
65. Astellas Pharma US, Inc. MYCAMINE (micafungin sodium) for injection [Internet]. 2013;Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021506s015lbl.pdf
66. Merck & Co., Inc. CANCIDAS (caspofungin acetate) for injection [Internet]. 2013. Available from: http://www.merck.ca/assets/en/pdf/products/cancidas-pm-e.pdf [Cited 24 October 2013]
67. Vicuron Pharmaceuticals. ERAXIS (Anidulafungin) for injection [Internet]. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021632s000,021948s000lbl.pdf [Cited 24 October 2013]
68. Gupta AK, Daigle D, Paquet M. Therapies for onychomycosis: a systematic review and network meta-analysis of mycological cure. J Am Podiatr Med Assoc 2014. [Epub ahead of print]
69. Gan VN, Petruska M, Ginsburg CM. Epidemiology and treatment of tinea capitis: ketoconazole vs. griseofulvin. Pediatr Infect Dis J 1987;6:46-9
70. Tanz RR, Hebert AA, Esterly NB. Treating tinea capitis: should ketoconazole replace griseofulvin? J Pediatr 1988;112:987-91
71. Shemer A, Nathansohn N, Kaplan B, Trau H. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 1999;10:19-23
72. Farschian M, Yaghoobi R, Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002;13:73-6
73. Yazdanpanah MJ, Azizi H, Suizi B. Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor. Mycoses 2007;50:311-13
74. Bhogal CS, Singal A, Baruah MC. Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study. J Dermatol 2001;28:535-9
75. Tarantino G, Conca P, Basile V, et al. A prospective study of acute druginduced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410-15
76. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994;30:677-98; quiz 698-700
77. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994;30:911-33; quiz 934-6
78. Merck & Co., Inc. Noxafil® (posaconazole) [Internet]. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205596s000lbl.pdf [Cited 24 October 2014]